The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Novel immunotherapy combinations for SCLC
Ticiana Leal, MD, Winship Cancer Institute, Atlanta, GA, discusses emerging immunotherapy combinations in small cell lung cancer (SCLC). The current standard of care for patients with extensive stage SCLC is a combination of chemotherapy and immunotherapy, however most patients still experience disease progression. The Phase II SWOG S1929 trial (NCT04334941) investigated atezolizumab and talazoparib, with SLFN11 as a predictive biomarker, while other studies targeted immunosuppressants. The Phase III ETER701 trial (NCT04234607), assessed anlotinib, a tyrosine kinase inhibitor (TKI) with TQB2450, a PD-L1 inhibitor, whereas the Phase II CeLEBrATE trial (NCT04730999), assessed bevacizumab and atezolizumab. Dr Leal also comments on the ongoing Phase I/II trial (NCT04702880) of BMS-986012 as well as epigenetic regulators in conjunction with biomarker studies. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
